Atriva repurposes cancer drug candidates to create universal flu treatment

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors originally developed as cancer treatments to create a drug that can tackle all known and likely future strains of the influenza virus.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Rainer Lichtenberger – CEO, Atriva Therapeutics